CN108392667A - 具有组织诱导功能的淡化疤痕医用敷料及其制备方法 - Google Patents
具有组织诱导功能的淡化疤痕医用敷料及其制备方法 Download PDFInfo
- Publication number
- CN108392667A CN108392667A CN201810143484.3A CN201810143484A CN108392667A CN 108392667 A CN108392667 A CN 108392667A CN 201810143484 A CN201810143484 A CN 201810143484A CN 108392667 A CN108392667 A CN 108392667A
- Authority
- CN
- China
- Prior art keywords
- medical
- polyurethane
- inducing function
- diaphragm
- tissue inducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 75
- 230000001939 inductive effect Effects 0.000 title claims abstract description 62
- 238000010612 desalination reaction Methods 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000004814 polyurethane Substances 0.000 claims abstract description 141
- 229920002635 polyurethane Polymers 0.000 claims abstract description 106
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 40
- 206010052428 Wound Diseases 0.000 claims abstract description 39
- 238000001179 sorption measurement Methods 0.000 claims abstract description 34
- 230000029663 wound healing Effects 0.000 claims abstract description 15
- 230000015556 catabolic process Effects 0.000 claims abstract description 7
- 238000006731 degradation reaction Methods 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 49
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- AYLRODJJLADBOB-QMMMGPOBSA-N methyl (2s)-2,6-diisocyanatohexanoate Chemical compound COC(=O)[C@@H](N=C=O)CCCCN=C=O AYLRODJJLADBOB-QMMMGPOBSA-N 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 18
- 239000000017 hydrogel Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- 235000010443 alginic acid Nutrition 0.000 claims description 15
- 229920000615 alginic acid Polymers 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 150000002009 diols Chemical class 0.000 claims description 14
- -1 poly ethylene Polymers 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 13
- 229920000570 polyether Polymers 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- 108010039918 Polylysine Proteins 0.000 claims description 12
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 12
- 238000010041 electrostatic spinning Methods 0.000 claims description 12
- 229920000656 polylysine Polymers 0.000 claims description 12
- 239000004970 Chain extender Substances 0.000 claims description 11
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 10
- 235000010980 cellulose Nutrition 0.000 claims description 10
- 150000004985 diamines Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 9
- 229920000954 Polyglycolide Polymers 0.000 claims description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 229940072056 alginate Drugs 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- 229920000728 polyester Polymers 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 8
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 claims description 8
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229920001971 elastomer Polymers 0.000 claims description 7
- 239000000806 elastomer Substances 0.000 claims description 7
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 229920002803 thermoplastic polyurethane Polymers 0.000 claims description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 229920005615 natural polymer Polymers 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 229920006264 polyurethane film Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229910052710 silicon Inorganic materials 0.000 claims description 5
- 239000010703 silicon Substances 0.000 claims description 5
- 229940126586 small molecule drug Drugs 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- WNPMPFBJTYCQEL-UHFFFAOYSA-N carbonic acid;ethyl carbamate Chemical compound OC(O)=O.CCOC(N)=O WNPMPFBJTYCQEL-UHFFFAOYSA-N 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 4
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 238000005266 casting Methods 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 239000010773 plant oil Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920003226 polyurethane urea Polymers 0.000 claims description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- ALVZNPYWJMLXKV-UHFFFAOYSA-N 1,9-Nonanediol Chemical class OCCCCCCCCCO ALVZNPYWJMLXKV-UHFFFAOYSA-N 0.000 claims description 2
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 claims description 2
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 claims description 2
- KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
- 229960000250 adipic acid Drugs 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000012661 block copolymerization Methods 0.000 claims description 2
- QVYARBLCAHCSFJ-UHFFFAOYSA-N butane-1,1-diamine Chemical compound CCCC(N)N QVYARBLCAHCSFJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000006227 byproduct Substances 0.000 claims description 2
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical class OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- SXCBDZAEHILGLM-UHFFFAOYSA-N heptane-1,7-diol Chemical class OCCCCCCCO SXCBDZAEHILGLM-UHFFFAOYSA-N 0.000 claims description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003999 initiator Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- KJOMYNHMBRNCNY-UHFFFAOYSA-N pentane-1,1-diamine Chemical compound CCCCC(N)N KJOMYNHMBRNCNY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- GGHDAUPFEBTORZ-UHFFFAOYSA-N propane-1,1-diamine Chemical compound CCC(N)N GGHDAUPFEBTORZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 238000004176 ammonification Methods 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 150000002402 hexoses Chemical class 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 6
- 238000005297 material degradation process Methods 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 49
- 210000003491 skin Anatomy 0.000 description 33
- 239000000853 adhesive Substances 0.000 description 23
- 230000001070 adhesive effect Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 8
- 229920003225 polyurethane elastomer Polymers 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229920000117 poly(dioxanone) Polymers 0.000 description 5
- 239000004417 polycarbonate Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000283977 Oryctolagus Species 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920005830 Polyurethane Foam Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 125000005442 diisocyanate group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000002362 mulch Substances 0.000 description 3
- 229920006255 plastic film Polymers 0.000 description 3
- 239000002985 plastic film Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000011496 polyurethane foam Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940070710 valerate Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical compound CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 229960005224 roxithromycin Drugs 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000009306 yunnan baiyao Substances 0.000 description 2
- FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- VDHWOHDSOHPGPC-UHFFFAOYSA-N 3,3-dihydroxyoxepan-2-one Chemical compound OC1(O)CCCCOC1=O VDHWOHDSOHPGPC-UHFFFAOYSA-N 0.000 description 1
- ULKFLOVGORAZDI-UHFFFAOYSA-N 3,3-dimethyloxetan-2-one Chemical compound CC1(C)COC1=O ULKFLOVGORAZDI-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- DSUFPYCILZXJFF-UHFFFAOYSA-N 4-[[4-[[4-(pentoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamoyloxy]butyl n-[4-[[4-(butoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamate Chemical group C1CC(NC(=O)OCCCCC)CCC1CC1CCC(NC(=O)OCCCCOC(=O)NC2CCC(CC3CCC(CC3)NC(=O)OCCCC)CC2)CC1 DSUFPYCILZXJFF-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- YKVIWISPFDZYOW-UHFFFAOYSA-N 6-Decanolide Chemical compound CCCCC1CCCCC(=O)O1 YKVIWISPFDZYOW-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- MAOYFMLUTBSVFC-QMMMGPOBSA-N C(C)OC([C@@H](NCCC)CCO)=O Chemical compound C(C)OC([C@@H](NCCC)CCO)=O MAOYFMLUTBSVFC-QMMMGPOBSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 239000009413 Chuanxinlian Substances 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical compound O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZSPPVLDEEFYYTQ-UHFFFAOYSA-N dimethyl benzene-1,2-dicarboxylate prop-1-ene Chemical compound C=CC.C(C=1C(C(=O)OC)=CC=CC1)(=O)OC ZSPPVLDEEFYYTQ-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- DNYGXMICFMACRA-UHFFFAOYSA-N gentamicin C1A Natural products O1C(CNC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N DNYGXMICFMACRA-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical class CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960004744 micronomicin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229950011346 panipenem Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- CWEFIMQKSZFZNY-UHFFFAOYSA-N pentyl 2-[4-[[4-[4-[[4-[[4-(pentoxycarbonylamino)phenyl]methyl]phenyl]carbamoyloxy]butoxycarbonylamino]phenyl]methyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCCCCC)=CC=C1CC(C=C1)=CC=C1NC(=O)OCCCCOC(=O)NC(C=C1)=CC=C1CC1=CC=C(NC(=O)OCCCCC)C=C1 CWEFIMQKSZFZNY-UHFFFAOYSA-N 0.000 description 1
- 125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 108010052780 polyasparagine Proteins 0.000 description 1
- 108010077051 polycysteine Proteins 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 108010057904 polyisoleucine Proteins 0.000 description 1
- 108010050934 polyleucine Proteins 0.000 description 1
- 108010087948 polymethionine Proteins 0.000 description 1
- 108010039177 polyphenylalanine Proteins 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920000909 polytetrahydrofuran Polymers 0.000 description 1
- 108010011723 polytryptophan Proteins 0.000 description 1
- 108010033949 polytyrosine Proteins 0.000 description 1
- 108010033356 polyvaline Proteins 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000009254 shuang-huang-lian Substances 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- UQMGAWUIVYDWBP-UHFFFAOYSA-N silyl acetate Chemical class CC(=O)O[SiH3] UQMGAWUIVYDWBP-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004636 vulcanized rubber Substances 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A61F13/01017—
-
- A61F13/01029—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/0203—Adhesive plasters or dressings having a fluid handling member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Abstract
本发明提供一种具有组织诱导功能的淡化疤痕医用敷料及其制备方法,所述具有组织诱导功能的淡化疤痕医用敷料包含具有孔隙率和厚度的医用聚氨酯膜片、吸液层和背衬层,所述吸液层和背衬层依次叠设于医用聚氨酯膜片的上方,所述可医用聚氨酯为与皮肤接触的接触创伤层。本发明采用了具有组织诱导功能的带有一定孔隙率和厚度的医用聚氨酯膜片作为贴覆伤口的细胞爬行支架层,在伤口愈合的过程中,细胞通过本发明的膜片支架结构缓慢爬行生长,由于可降解材料降解时间不一,致使组织吸收时间不一,创面细胞的爬行生长均匀程度不一,从而形成了类皮肤纹理结构,防止大块疤痕的生成。
Description
技术领域
本发明属于医用敷料领域,具体涉及一种具有组织诱导功能的淡化疤痕医用敷料,该敷料包含一定孔隙率和厚度的医用聚氨酯(PU)片状结构、吸液层和背衬层,所述吸液层和背衬层依次叠设于聚氨酯膜片的上方,所述医用聚氨酯为与皮肤接触的接触创伤层,其中医用聚氨酯片状结构孔径为10-300μm、厚度为0.01-0.5mm。
背景技术
现实生活中,烧烫伤、交通事故、机械性损伤的情况时有发生,轻度的伤口采用药物或者其它手段可以治愈,但是稍微严重的情况,伤及到真皮层,有可能会涉及到植皮手术,这样无论是在植皮部位还是在取皮部位,亦或是自愈部位,均会出现比较明显的疤痕,虽然控制了病情但却给心理上留下了较大的阴影。
长久以来,人们对医用敷料的定义一般为:以清洁和保护伤口为目的,这种传统意义上的敷料只是对伤口有一个保护的作用。1962年,英国科学家George Winter博士发现,潮湿的环境有利于伤口愈合,自此,基于这一思路的各种形式的湿性敷料广泛发展起来,包括水胶体敷料、水凝胶敷料等。水凝胶敷料具有可以明显缓解疼痛,吸收大量伤口渗出液,透气保湿,且透明可以观察伤口的愈合情况等优点,得到了各国研究开发者的普遍重视。湿性敷料可以在传统敷料的基础上为伤口提供一个湿性的环境,从而加速伤口愈合。在湿性敷料的基础上发展出来各种功能性敷料,包括含有中药止血、化药消炎成分的敷料、银离子敷料、壳聚糖等生物湿性敷料应运而生。针对大伤口、大渗液需要的产品为负压引流产品,中国发明专利CN103691010B给出了负压引流产品的具体制备方法;中国发明专利CN105107015A给出来一种抗菌促愈合的生物泡沫敷料的制备方法;中国发明CN105169455A给出了一种烧烫伤外用急救医用敷料及其制备方法。湿性敷料发展迅速,然而在加速伤口愈合的过程中,疤痕不可避免的产生。
众所周知,疤痕一旦产生再想去除是非常困难的。因此又有了另一个领域的产品应运而生,即去疤痕产品,此类产品大多含有有机硅成分,例如中国发明专利CN201710253038.3公开了一种祛疤痕硅酮凝胶及其制备方法;中国发明专利CN201610794712.4公开了一种自带包装的医用硅凝胶疤痕贴及其生产工艺;中国实用新型专利CN201620357808.X公开了一种用于抑制瘢痕增生的疤痕贴,但其成分包括异黄酮和硅凝胶;中国发明专利CN201510883010.9公开了一种类人胶原蛋白疤痕修复硅凝胶。上述几项专利虽然均含有硅凝胶,但是大部分是在疤痕形成后而针对祛疤痕儿产生的产品、专利及技术。
医用聚氨酯材料具有优良的生物相容性、可黏合性和抗血栓性,同时还具有优良的力学性能,在医用生物材料中扮演了十分重要的角色。热塑性聚氨酯弹性体(tpu)在医疗中使用的聚氨酯弹性体主要是热塑性聚氨酯(tpu)弹性体。其加工方式可为注射成型、挤出成型或溶液浇汪成型。热塑性聚氨酯是由软段(长链的低聚物二醇)及硬段(二异氰酸酯及扩链剂)所组成的线性嵌段聚合物,由于硬段具有很强的极性,硬段之间通过氢键形成硬段微相区,分布于软段基体中,形成一种物理性交联点,使弹性体具有硫化橡胶的弹性回复性能。由于聚氨酯分子结构中的软硬段存在极性差异,这种结构使它与生物体具有良好的相容性。由于tpu加工方便,性能优异,已广泛应用于多种医疗及保健制品,如可用于长期及短期植入人体的医用材料等。tpu的性能根据原料二异氰酸酯、低聚物二醇及短链二醇扩链剂的品种及配比而定。在医疗用聚氨酯弹性体制备中,两种常用二异氰酸酯是芳香族的4,4’-二苯甲烷二异氰酸酯(mdi)及脂肪族的亚甲基二环己基二异氰酸酯(hmdi)。常用的低聚物多元醇有聚四亚甲基醚二醇(ptmeg)、聚酯二醇及聚碳酸酯二醇等。由于以ptmeg与mdi或hmdi制成的聚氨酯弹性体具有优异的机械强度、耐水性及生物相容性,ptmeg是用于医疗用聚氨酯材料的一种重要的低聚物二醇,聚酯二醇也可用于医疗级聚氨酯材料,目前注意力已集中于聚碳酸酯二醇。最常用的扩链剂是1,4-丁二醇(bd)。比如:(1)脂肪族聚醚氨酯以hmdi或六亚甲基二异氰酸酯(hdi)、ptmeg及bd为原料的tpu具有良好的生物相容性、强度及可加工性。如美国thermedics公司(原thermo electron公司)的医用聚氨酯tecoflex的组成是pt-meg-hmdi-bd,80年代美国dupont公司的医用聚氨酯adiprenelw 500的原料是ptmeg-hdi-bd;(2)脂肪族聚碳酸酯氨酯这类tpu以hmdi、聚碳酸酯二醇为原料。它具有与聚醚氨酯类似的生物相容性,耐氧化降解性及生物稳定性更好,有良好的强度和操作性。商品有thermedics公司的carbothane、polymedica工业公司的chronoflex等。这种tpu能抵抗酶诱发的降解,用于人造心脏及血管;(3)芳香族聚碳酸酯氨酯其原料是mdi、聚碳酸酯二醇和bd。它具有与脂肪族聚碳酸酯氨酯类似的生物稳定性及生物相容性,芳香族聚氨酯的强度和耐溶剂性,缺点是可能产生mda及黄变。商品有美国聚合物技术集团公司的bionate等;(4)芳香族聚酯氨酯以聚己内酯或聚己二酸酯mdi和bd为原料,这类tpu的强度比ptmeg型聚氨酯的高,但易于水解和受微生物的侵袭。商品有bf goodrich公司的estane、dow化学公司的pellethane等;(5)聚氨酯-脲弹性体例如bayer(美国)公司的texin5590是一种脂肪族聚醚脲型tpu,设计用于与血液接触的场合,以及管形材料及导液管等短期植入装置。美国ethicon公司的医用聚氨酯弹性体biomer是由ptmeg和mdi反应生成端异氰酸酯基预聚物。在二甲基甲酰胺(dmf)溶剂中以乙二胺为扩链剂,浇注而成的线性聚氨酯-脲嵌段聚合物。corvita公司90年代研制的植入人体器官用tpu弹性体材料corethane,未透露组成成分,据称它具有与广泛使用的芳香族聚醚聚氨酯相似的性能,但在人体内不会受酶的影响而降解。该公司还在开发研制聚氨酯共聚物以及与其它聚合物的复合材料,用于体内植入物。其它聚氨酯弹性体除tpu之外,一些聚氨酯弹性体预聚物及共聚物也应用于医疗场合。例如,美国kontron公司的cardiothane是一种聚氨酯-有机硅弹性体。它是在由mdi和聚四氢呋喃醚二醇生成的预聚物中加入分子量较大的硅氧烷交联剂(端乙酰氧基硅氧烷),由微量水交联而生成的交联聚合物,采用溶液浇注法成型。avcothane是美国avco-ereto公司开发的聚氨酯-聚二甲基硅氧烷嵌段共聚物,此材料在外循环血泵中用,可以采用浸渍成型,有很好的机械性能,能满足人工心脏苛刻的要求。聚氨酯弹性体可以多种形式用于医疗,例如可以ptmeg-mdi预聚体销售,根据所需的形状进行现场浇注成型。还可制成微孔弹性体。人工心脏上用的聚氨酯弹性体隔膜材料,为聚醚型热塑性聚氨酯,其组成成分一般是聚四呋喃醚二醇(ptmeg)-mdi(或hdi)-bd或乙二胺,溶液浇注或注射成型,也有采用聚氨酯-硅烷嵌段共聚物。
随着医学生物工程及组织生物学的发展,理想的创面敷料应具有以下功能:能诱导瘢痕组织沿材料设计的结构生长,吸收多余的渗出物,与伤口接触面保持一定的湿度,具有良好的粘附及生物相容性,具有良好的生物降解性,具有一定的抗菌性,防止微生物、有害微粒及其他有害物质污染伤口等。赖氨酸,也称为L -赖氨酸盐酸盐,是一种必需氨基酸。它是人体所必需的营养物质,但是身体不能自己产生它。它必须通过日常饮食和营养补品获得。作为一种氨基酸,它是蛋白质必不可少的组成部分。它和其他营养一起形成胶原蛋白。大量文献报道了赖氨酸在组织再生中的重要作用,我们研究发现,以赖氨酸二异氰酸酯为硬段的聚氨酯,具有诱导成纤维细胞和胶原蛋白沿着生物材料进行生长的功能,检索了。具有防止疤痕生长的具有组织诱导功能的医用敷料一直没有产品上市,随着消费升级,人们对于皮肤修复的美观度要求日益增加,市场上需要一款既能促进伤口愈合,又能实现生长减少甚至无疤痕生成的产品。
发明内容
本发明要解决的技术问题是提供一种具有组织诱导功能的淡化疤痕医用敷料及其制备方法,该敷料由赖氨酸二异氰酸酯做为硬段的聚氨酯材料制成类皮肤结构,带有适合细胞生长的孔径和厚度,该材料可以诱导皮肤组织根据材料的纹理生长,根据材料降解的先后顺序依次生长出与原有皮肤纹理接近一致的纹路,避免大块疤痕的发生,达到了满足患者美化创伤皮肤的需要。
本发明公开了一种具有组织诱导功能的淡化疤痕医用敷料,包含具有孔隙率和厚度的医用聚氨酯(PU)膜片、吸液层和背衬层,所述吸液层和背衬层依次叠设于医用聚氨酯膜片的上方,所述医用聚氨酯膜片为与皮肤接触的接触创伤层,其中,所述医用聚氨酯膜片的厚度为0.01-0.5mm,其上的微孔孔径为10-300μm。
本发明中的医用聚氨酯膜片、吸液层和背衬层可以是整体一次性使用,也可以是吸液层与背衬层与医用聚氨酯膜片分离,吸液层与背衬层可以多次更换。所述吸液层的厚度为0.01-2cm,优选0.05-0.5cm。
其中,所述医用聚氨酯膜片由厚薄不一、孔径大小不一的多孔结构、降解时间不同的材料制成。
其中,所述医用聚氨酯膜片的材料选自聚醚型、聚酯-聚醚型、天然高分子型(主要包括淀粉、纤维素和木质素)以及植物油基型可生物降解 PU、脂肪族聚醚氨酯、聚氨酯-丙烯酸酯水凝胶,脂肪族聚碳酸酯氨酯、聚氨酯-脲弹性体、聚氨酯-聚二甲基硅氧烷嵌段共聚物,聚醚型热塑性聚氨酯中的一种或两种。
本发明所述医用聚氨酯膜片优选以赖氨酸二异氰酸酯做硬段的聚氨酯,软段可以是以聚乙二醇为引发剂,LA、GA、CL、PDO、己二酸酐得聚合物二醇,扩链接选自扩链剂二元醇或二元胺或类二元胺,具体选自乙二醇、二甘醇、四甘醇、1,3- 丙二醇、1,4- 丁二醇、1,6-己二醇、1,7- 庚二醇、1,8- 辛二醇、1,9- 壬二醇、1,10- 癸二醇、乙二胺、丙二胺、丁二胺、戊二胺、类二元胺中的一种或两种。
优选的,所述医用聚氨酯膜片中聚氨酯的软段原料选自聚氨酯、聚酯、聚醚、聚氨基酸中的一种或两种组合。具体选自聚戊内酯、聚-ε-癸内酯、聚丙交酯、聚乙交酯、聚丙交酯与聚乙交酯的共聚物、聚丙交酯-乙交酯的共聚物、聚-ε-己内酯、聚羟基丁酸、聚羟基丁酸酯、聚羟基戊酸酯、聚羟基丁酸酯-共-戊酸酯、聚(1,4-二噁烷-2,3-二酮)、聚(1,3-二噁烷-2-酮)、聚-对-二氧杂环己酮、聚酸酐、聚马来酸酐、聚羟基甲基丙烯酸酯、纤维蛋白、聚氰基丙烯酸酯、聚己内酯丙烯酸二甲酯、聚-β-马来酸、聚己内酯丙烯酸丁酯、由蓖麻油(CO)、微生物发酵的聚羟基丁酸戊酸酯(PHBV)和化学合成的聚乙烯醇(PVA),制备的生物基聚氨酷材料、多嵌段聚合物比如:来自寡聚己内酯二醇、寡聚二氧杂环己酮二醇、聚醚酯多嵌段聚合物、聚新戊内酯、聚乙醇酸碳酸三甲酯、聚己内酯-乙交酯、聚(g-谷氨酸乙酯)、聚甘氨酸、聚丙氨酸、聚缬氨酸、聚亮氨酸、聚异亮氨酸、聚苯丙氨酸和聚脯氨酸、聚色氨酸、聚丝氨酸、聚酪氨酸、聚半胱氨酸、聚蛋氨酸、聚天冬酰胺、聚谷氨酰胺和聚苏氨酸、聚天冬氨酸和聚谷氨酸、聚赖氨酸、聚精氨酸和聚组氨酸、或者是不同氨基酸的聚合物多肽,优选带游离氨基的由碱性氨基酸聚合而成的比如聚精氨酸、聚赖氨酸和聚组氨酸中的一种或两种组合。
进一步优选医用聚氨酯(聚酯型PU、聚醚型PU、聚酯-聚醚型PU、天然高分子PU 和植物油基型 PU及公开资料文献可检索的各种可降解聚氨酯材料)、医用聚酯(聚乙交酯、聚丙交酯与聚乙交酯的共聚物、聚-ε-己内酯、聚己内酯-乙交酯、聚己内酯-丙交酯、聚(g-谷氨酸乙酯)、聚赖氨酸和聚赖氨酸PU中的一种或两种组合,优选聚合物数均分子量小于20万,更优选聚合物数均分子量小于10万的高分子材料。
更优选聚酯型PU,具体包括以PCL、GA为软段并以赖氨酸二异氰酸酯为硬段的降解时间在1个月以内的PU材料、用赖氨酸二异氰酸酯交联多聚赖氨酸的PU材料、天然高分子羧甲基纤维素或透明质酸为软段并以赖氨酸二异氰酸酯为硬段的PU材料、聚乙交酯、聚丙交酯与聚乙交酯的共聚物、聚己内酯-乙交酯以及聚赖氨酸中的一种或两种组合,制成的可吸收医用聚氨酯膜片的孔径为10-300μm、厚度为0.01-0.5mm。
更优先安全性好无细胞毒性的聚酯型PU,具体包括以PCL、GA为软段并以赖氨酸二异氰酸酯为硬段的降解时间在14天左右的PU材料、用赖氨酸二异氰酸酯交联多聚赖氨酸的PU材料、天然高分子羧甲基纤维素或透明质酸为软段并以赖氨酸二异氰酸酯为硬段的PU材料,本发明所述的无细胞毒性PU材料,其中扩链剂选自有两个氨基的氨基酸(精氨酸、赖氨酸、羟脯胺酸)、也可以选自通过1、3丙二醇与两分子氨基酸酯化反应后通过两个酯键相连的拥有两个活波氨基的化合物
进一步,所述聚氨酯膜片的制备材料还包括促进伤口愈合的高分子材料、具有生物抗炎活性的小分子药物,其中,所述高分子材料为透明质酸钠、透明质酸锌、PVA、PVP、聚赖氨酸、聚谷氨酸、硫酸软骨素、羧甲基纤维素钠、壳聚糖、海藻酸盐、改性海藻酸盐及其降解成氨基己糖和 N- 乙酰氨基葡萄糖的海藻酸盐中的一种或两种组合;所述小分子药物为多肽类、氨基酸以及各种抗炎药物的一种或两种组合。其中,抗炎药物具体包括抗菌消炎药物,目前临床常用的主要有以下几类:抗生素类、磺胺类、甲硝唑类、抗真菌类、中成药类。比如β-内酰胺类抗生素:1、青霉素类抗生素:如青霉素G、青霉素V、普鲁卡因青霉素、阿莫西林、氨芐青霉素、美洛西林、羧苄青霉素、亚胺培南(泰能)、美罗培南、帕尼培南;2、头孢菌素类抗生素:如、头孢氨苄(先锋4)、头孢唑林钠(先锋5)、头孢拉定(先锋6)、头孢羟氨苄、头孢曲松钠(菌必治);3、碳氢霉烯类和青霉烯类:如亚胺培南;4、单环类抗生素:如氨曲南;氟喹诺酮类抗菌素药物:如环丙沙星、氧氟沙星、诺氟沙星、盐酸左氧氟沙星、加替沙星;5、大环内酯类抗生素:如罗红霉素、阿奇霉素、克拉霉素;6、氨基糖苷类抗生素:庆大霉素、丁氨卡那霉素、小诺霉素;7、其它抗生素等,还有中成药类,比如:云南白药、抗泌尿系统感染常用的三金片活性成分,上呼吸道感染常用的双黄连口服液及其注射液、还有连蒲双清片活性成分、牛黄解毒丸(片)活性成分、穿心莲片活性成分、银黄胶囊活性成分、炎可宁胶囊活性成分等。
促进伤口愈合的多肽或蛋白类活性成分,包括表皮生长因子(EGF)转化生长因子β超家族(TGF)、成骨形态发生蛋白(BMP)、成纤维细胞生长因子(FGF)、胰岛素样生长因子(IGF)等。
所述医用聚氨酯膜片采用如下几种制备方法:
第一种:使用不同比例的CL、PDO和不同分子量的PEG(分子量200-2000)合成线型聚己内酯二醇,将其产物与赖氨酸二异氰酸酯反应,使用不同的二元醇作为扩链剂,辛酸亚锡(总量的0.01-0.1wt%)作为催化剂,反应得到医用聚氨酯膜片。
第二种:使用特定分子量(分子量范围为200-2000)的聚乳酸如PLA、PGA、PLGA和不同二元醇合成线型乳酸-乙醇酸共聚多元醇,将产物与不同的二异氰酸酯反应,辛酸亚锡(总量的0.01-0.1wt%)作为催化剂,反应得到医用聚氨酯膜片。
第三种:使用不同分子量的LA、GA聚合物二醇、指 已二酸聚酯二元醇、乙二酸聚酯二元醇作为软链,将其与LDI和不同小分子二醇或二胺进行反应,辛酸亚锡(总量的0.01-0.1wt%)作为催化剂,反应得到医用聚氨酯膜片。
第四种:使用端羟基聚二甲基硅氧烷(分子量范围为2000-10000)作为软段,将其与LDI和小分子二醇或二胺进行反应,辛酸亚锡(总量的0.01-0.1wt%)作为催化剂,形成由软段和硬段交替排列组成的有机硅-聚氨酯嵌段共聚物。
其中,所述吸液层的材料选自高吸水的聚合物,包括海藻酸盐、改性海藻酸盐及其降解成氨基己糖和 N- 乙酰氨基葡萄糖的海藻酸盐、淀粉接枝丙烯腈、淀粉接枝亲水性单体、聚丙烯酸盐类、醋酸乙烯酯共聚物、改性聚乙烯醇类、羧甲基纤维素、纤维素接枝丙烯腈、纤维素接枝丙烯酸盐、纤维素黄原酸化接枝丙烯酸盐、纤维素接枝丙烯酰胺、纤维素羧甲基后环氧氯丙烷交叉交联中的一种;高分子抗菌吸水材料、聚氨基酸、壳聚糖、聚赖氨酸PU、聚乙烯醇中的一种;进一步包括在医用聚氨酯膜片上涂覆有硅凝胶层,所述硅凝胶层选用具有修复疤痕的硅凝胶或聚二甲基硅氧烷相关的有机硅材料;所述背衬层为具有粘结作用的医用透气贴膜为医用聚氨酯薄膜、离型膜或医用背衬膜。
本发明的所述医用聚氨酯膜片的制备材料还包括促进伤口愈合的高分子材料、具有生物抗炎活性的小分子药物、促进伤口愈合的活性成分,其中,所述高分子材料为聚乙烯醇及其衍生物(PVA)、聚乙烯吡咯烷酮及其衍生物(PVP)、透明质酸钠、透明质酸锌、海藻酸盐、改性海藻酸盐及其降解成氨基己糖和 N- 乙酰氨基葡萄糖的海藻酸盐中的一种或两种组合;所述小分子药物为多肽类、氨基酸以及各种抗炎药物的一种或两种组合。
本发明还提供一种具有组织诱导功能的淡化疤痕医用敷料的制备方法,包括如下步骤:
(1-1)通过静电纺丝或其它手段,将聚氨酯和促进伤口愈合的高分子材料纺成具有孔径为10-300μm、厚度为0.02-0.5mm的具有组织诱导功能的医用聚氨酯膜片;
(1-2)选具有强吸水作用或抗菌作用的高分子材料制备成多孔的吸液层;
(1-3)选择合适的透气膜作为背衬层;
(1-4)将步骤(1-1)、步骤(1-2)和步骤(1-3)制备的医用聚氨酯膜片、吸液层和被衬层按顺序紧密贴合,晾干或烘干,即形成具有组织诱导功能的淡化疤痕医用敷料;
其中,步骤(1-2)中的高分子材料优选PVA、PVP和透明质酸中的一种。
所述具有组织诱导功能的淡化疤痕医用敷料也可以采用如下制备方法,包括如下步骤::
(2-1)通过聚氨酯用有机溶解溶解,浇筑工艺制成具有孔径为10-300μm、厚度为0.02-0.5mm的具有组织诱导功能的医用聚氨酯膜片,均匀喷涂上硅凝胶;
(2-2)选具有强吸水作用或抗菌作用的高分子材料制备成多孔的吸液层;
(2-3)选择合适的透气膜作为背衬层;
(2-4)将步骤(2-1)、步骤(2-2)和步骤(2-3)制备的医用聚氨酯膜片、吸液层和被衬层按顺序紧密贴合,晾干或烘干,即形成具有组织诱导功能的淡化疤痕医用敷料;
所述具有组织诱导功能的淡化疤痕医用敷料还可以采用如下制备方法,包括如下步骤:
(3-1)将聚氨酯溶于有机溶剂中,加水和乳化剂搅拌后制成粘稠乳液状,真空干燥或冻干制成具有孔径为10-300μm、厚度为0.02-0.5mm的具有组织诱导功能的多孔医用聚氨酯膜片;
(3-2)选具有强吸水作用或抗菌作用的高分子材料制备成多孔的吸液层;
(3-3)选择合适的透气膜作为背衬层;
(3-4)将步骤(3-1)、步骤(3-2)和步骤(3-3)制备的医用聚氨酯膜片、吸液层和被衬层按顺序紧密贴合,晾干或烘干,即形成具有组织诱导功能的淡化疤痕医用敷料。
本发明还提供一种具有组织诱导功能的淡化疤痕医用敷料的用途,用于创面修复,能诱导疤痕组织沿设定的结构生长,使疤痕组织形成类皮肤结构,美化皮肤,同时能吸收多余的渗出物,与伤口接触面保持一定的湿度,具有良好的粘附及生物相容性,利于伤口愈合。
本发明的上述技术方案的有益效果如下:本发明采用了具有组织诱导功能的带有一定孔隙率和厚度的医用聚氨酯膜片作为贴覆伤口的细胞爬行支架层,在伤口愈合的过程中,细胞通过本发明的膜片支架结构缓慢爬行生长,由于可降解材料降解时间不一,致使组织吸收时间不一,创面细胞的爬行生长均匀程度不一,从而形成了类皮肤纹理结构,防止大块疤痕的生成。
附图说明
图1为本发明的结构分解示意图;
图2为本发明实施例十的动物实验图片。
附图标记说明:
1、医用聚氨酯膜片;2、吸液层;3、背衬层。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚,下面将结合附图及具体实施例进行详细描述。
如图1所示,本发明提供一种具有组织诱导功能的淡化疤痕医用敷料,包含具有组织诱导功能的带有一定孔隙率和厚度的医用聚氨酯膜片1、吸液层2和背衬层3,所述吸液层2和背衬层3依次叠设于医用聚氨酯膜片1的上方,所述医用聚氨酯膜片1为与皮肤接触的接触创伤层。
所述聚氨酯膜片的厚度为0.01-0.5mm,其上微孔的孔径为10-300μm。所述吸液层的厚度为0.1-2cm,优选0.1-0.5cm。
下面将结合具体实施例进行详细描述。
实施例1
用于渗液少的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
1-)将可降解聚氨酯溶解在三氯甲烷溶液中,配成15%溶液,采用静电纺丝技术纺成具有孔径为10-150μm、厚度为0.1-0.2mm的膜,均匀涂覆一层硅凝胶,即为医用聚氨酯膜片;
1-2)将透明质酸钠凝胶均匀涂覆在步骤1-1)所得医用聚氨酯膜片上,烘干或晾干;
1-3)将带有粘性的背衬层覆盖在步骤1-2)所得膜片上,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
实施例2
用于渗液少的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
2-1)将可降解聚氨酯溶解在三氯甲烷溶液中,配成15%溶液,PVP用乙醇配成15%溶液,采用静电纺丝技术对喷,纺成重量比1:1的具有孔径为10-150μm,厚度为0.05-0.1mm的膜,均匀涂覆一层聚赖氨酸PU(先配成1%水凝胶备用),即为医用聚氨酯膜片;
2-2)将带有粘性的背衬层覆盖在步骤2-1)所得医用聚氨酯膜片上,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
实施例3
用于渗液多的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
3-1)将PLGA(数均分子量5万,LA:GA=6:4),配成15%氯仿溶液,采用静电纺丝技术纺成具有孔径为100-300μm、厚度为0.2-0.3mm的膜,均匀喷涂上硅凝胶,形成医用聚氨酯膜片;
3-2)将海藻酸钠配成凝胶状,均匀涂覆在步骤3-1)所得的医用聚氨酯膜片上,烘干或晾干;
3-3)选择合适的透气膜做为皮肤粘结背衬层,备用;
3-4)将步骤(2)(3)得的医用聚氨酯膜片和皮肤粘结背衬层紧密贴合,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
实施例4
用于渗液多的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
4-1)将以1、3丙二醇为扩链剂,PEG200引发CL得到的聚合二醇为软段,LDI为硬段的聚氨酯(分子量7-8万)2份, PLGA(数均分子量3万,LA:GA=6:4)1份,配成15%氯仿溶液,采用静电纺丝技术纺成具有孔径为100-300μm、厚度为0.2-0.3mm的膜,均匀喷涂上硅凝胶,形成医用聚氨酯膜片;
4-2)将抗炎药物云南白药添加在海藻酸钠凝胶溶液中,均匀涂覆在步骤4-1)所得的医用聚氨酯膜片上,烘干或晾干;
4-3)选择合适的透气膜做为皮肤粘结背衬层,备用;
4-4)将步骤(2)(3)制得的医用聚氨酯膜片和皮肤粘结背衬层紧密贴合,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
实施例5
用于渗液适中的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
5-1)将以1、4丁二胺为扩链剂,PEG600引发PDO得到的聚合二醇为软段,LDI为硬段的聚氨酯(分子量5-7万),配成15%氯仿溶液,PVP配成15%乙醇溶液,两者比例3:1,采用静电纺丝技术纺成具有孔径为50-200μm、厚度为0.1-0.2mm的医用聚氨酯膜片;
5-2)将透明质酸锌配成凝胶状,均匀涂覆在步骤5-1)所得医用聚氨酯膜片上,烘干或晾干备用;
5-3)选择合适的透气膜做为皮肤粘结背衬固定层,备用;
5-4)将步骤5-2)、5-3)制得的医用聚氨酯膜片和皮肤粘结背衬固定层紧密贴合,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料;
实施例6
用于渗液适中的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
6-1)将 PU(以PCL-GA为软段、赖氨酸二异氰酸酯为硬段的PU,(分子量5-7万),配成15%氯仿溶液,PVA溶解在50%乙醇溶液中,配成15%溶液,两者重量比为3:1,采用静电纺丝技术纺成具有孔径为10-150μm,厚度为0.05-0.1mm的医用聚氨酯膜片;
6-2)将聚氨酯PU添加抗炎药物罗红霉素配成凝胶状,均匀涂覆在步骤6-1)所得医用聚氨酯膜片上,烘干、冻干或晾干备用;
6-3)选择合适的透气膜做为皮肤粘结背衬固定层,备用;
6-4)将步骤6-1)、6-2)、6-3)制得的医用聚氨酯膜片和皮肤粘结背衬固定层按顺序紧密贴合,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料;
6-5)将步骤6-2)和6-3)制得的医用聚氨酯膜片和皮肤粘结背衬固定层紧密贴合,可以作为渗液吸附满以后的更换层。
实施例7
用于渗液适中的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
7-1)将 PU(以PCL-GA为软段、赖氨酸二异氰酸酯为硬段的PU,数均分子量3-4万),配成15%氯仿溶液,采用静电纺丝技术纺成具有孔径为10-150μm、厚度为0.05-0.1mm的医用聚氨酯膜片;
7-2)将羧甲基纤维素钠制成的薄膜备用;
7-3)选择合适的透气膜做为皮肤粘结背衬固定层,备用;
7-4)将步骤7-1)、7-2)、7-3)中的医用聚氨酯膜片、薄膜和皮肤粘结背衬固定层按顺序紧密贴合,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料;
7-5)将步骤7-2)、7-3)的薄膜和皮肤粘结背衬固定层紧密贴合,可以作为渗液吸附满以后的更换层。
实施例8
用于渗液较少的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
8-1)将 PU(以PC为软段、赖氨酸二异氰酸酯为硬段的PU,数均分子量3-4万),配成15%氯仿溶液,采用静电纺丝技术纺成具有孔径为10-150μm、厚度为0.05-0.1mm的医用聚氨酯膜片;
8-2)将多聚赖氨酸配成凝胶,均匀涂覆在步骤8-1)所得医用聚氨酯膜片上,烘干或晾干备用;
8-3)选择合适的透气膜做为皮肤粘结背衬固定层,备用;
8-4)将步骤8-1)、8-2)、8-3)的医用聚氨酯膜片和皮肤粘结背衬固定层按顺序紧密贴合,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
实施例9
用于渗液较多的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
9-1)将 PU(以PDO为软段、赖氨酸二异氰酸酯为硬段的PU,数均分子量3-4万),配成15%氯仿溶液,采用静电纺丝技术纺成具有孔径为10-150μm、厚度为0.05-0.1mm的医用聚氨酯膜片;
9-2)将聚氨酯泡沫的上表面涂覆一层多聚赖氨酸,晾干或烘干备用;
9-3)选择合适的透气膜做为皮肤粘结背衬固定层,备用;
9-4)将步骤9-1)、9-2)、9-3)中的医用聚氨酯膜片和皮肤粘结背衬固定层按顺序紧密贴合,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料;
9-5)将步骤9-2)、9-3)中的医用聚氨酯膜片和皮肤粘结背衬固定层按紧密贴合,可以作为渗液吸附满以后的更换层。
实施例10 动物实验
取新西兰兔一只,踢掉背部的皮毛,用刮刀挂掉兔子表皮,制成皮肤损伤动物模型,如图2所示,其中在图2中新西兰兔的左侧伤口处贴上市售聚氨酯泡沫敷料,在新西兰兔的右上侧伤口处贴上本实施例6制成的敷料,在新西兰兔的右下侧伤口处贴上本实施例9制成的敷料,贴覆在兔子伤口上,隔两天观察,渗液吸满后更换敷料,两周后,伤口基本愈合,实验结果如附图2所示,从图中可以看出市售聚氨酯泡沫敷创面愈合速度快于本发明实施例产品,但愈合后留有疤痕,本发明样品虽然伤口愈合速度较慢,但基本不见明显的疤痕生成,为此,有理由相信本发明创造的产品在抑制疤痕生成方面有有非常有意义的应用价值。
实施例11
用于渗液适中的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
11-1)将用赖氨酸二异氰酸酯交联的聚赖氨酸PU,用注射用水制成水凝胶,铺膜冻干制成具有孔径为10-300μm、厚度为0.01-0.5mm的具有组织诱导功能的医用聚氨酯膜片;
11-2)选择合适的透气膜作为皮肤粘结背衬固定层;
11-3)将步骤11-1)、11-2)的医用聚氨酯膜片和皮肤粘结背衬固定层紧密贴合,晾干或烘干,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
实施例12
用于渗液适中的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
12-1)将 PU(以PCL-GA为软段、赖氨酸二异氰酸酯为硬段的PU,数均分子量2-3万),配成15%氯仿溶液,采用静电纺丝技术纺成具有孔径为10-150μm、厚度为0.05-0.1mm的膜片;
12-2)将用赖氨酸二异氰酸酯交联的聚赖氨酸PU,用注射用水制成水凝胶,铺膜冻干制成具有孔径为10-300μm、厚度为0.01-0.5mm的具有组织诱导和吸收渗液双重功能的医用聚氨酯膜片;
12-3)选择合适的透气膜作为皮肤粘结背衬固定层;
12-4)将步骤12-1)、12-2)、12-3)的膜片、医用聚氨酯膜片和皮肤粘结背衬固定层按顺序紧密贴合,晾干或烘干,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
实施例13
用于渗液适中的伤口的具有组织诱导功能的淡化疤痕医用敷料,其制备方法为:
13-1)将 PEG200或PEG300或PEG400或PEG600引发合成的PLGA(LA:GA=5:5,数均分子量3-4万),配成15%氯仿溶液,采用静电纺丝技术纺成具有孔径为10-150μm、厚度为0.05-0.1mm的膜片;
13-2)将用赖氨酸二异氰酸酯交联的聚赖氨酸PU,用注射用水制成水凝胶,铺膜冻干制成具有孔径为10-300μm、厚度为0.01-0.5mm的具有组织诱导和吸收渗液双重功能的医用聚氨酯膜片;
13-3)选择合适的透气膜作为皮肤粘结背衬固定层;
13-4)将步骤13-1)、13-2)、13-3)的膜片、医用聚氨酯膜片和皮肤粘结背衬固定层按顺序紧密贴合,晾干或烘干,即形成本实施例的具有组织诱导功能的淡化疤痕医用敷料。
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明所述原理的前提下,还可以作出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种具有组织诱导功能的淡化疤痕医用敷料,其特征在于,包含具有孔隙率和厚度的医用聚氨酯膜片、吸液层和背衬层,所述吸液层和背衬层依次叠设于医用聚氨酯膜片的上方,所述医用聚氨酯膜片为与皮肤接触的接触创伤层,其中,所述医用聚氨酯膜片的厚度为0.01-0.5mm,其上的微孔孔径为10-300μm。
2.根据权利要求1所述的具有组织诱导功能的淡化疤痕医用敷料,其特征在于,所述医用聚氨酯膜片的材料选自聚醚型、聚酯-聚醚型、天然高分子型以及植物油基型可生物降解PU、脂肪族聚醚氨酯、聚氨酯-丙烯酸酯水凝胶,脂肪族聚碳酸酯氨酯、聚氨酯-脲弹性体、聚氨酯-聚二甲基硅氧烷嵌段共聚物,聚醚型热塑性聚氨酯中的一种或两种。
3.根据权利要求1所述的具有组织诱导功能的淡化疤痕医用敷料,其特征在于,所述吸液层的材料选自高吸水的聚合物,包括海藻酸盐、改性海藻酸盐及其降解成氨基己糖和 N-乙酰氨基葡萄糖的海藻酸盐、淀粉接枝丙烯腈、淀粉接枝亲水性单体、聚丙烯酸盐类、醋酸乙烯酯共聚物、改性聚乙烯醇类、羧甲基纤维素、纤维素接枝丙烯腈、纤维素接枝丙烯酸盐、纤维素黄原酸化接枝丙烯酸盐、纤维素接枝丙烯酰胺、纤维素羧甲基后环氧氯丙烷交叉交联中的一种;或者高分子抗菌吸水材料、聚氨基酸、壳聚糖、聚赖氨酸、聚乙烯醇中的一种。
4.根据权利要求1所述的具有组织诱导功能的淡化疤痕医用敷料,其特征在于,在所述医用聚氨酯膜片上涂覆有硅凝胶层,所述硅凝胶层选用具有修复疤痕的硅凝胶或聚二甲基硅氧烷相关的有机硅材料。
5.根据权利要求1所述的具有组织诱导功能的淡化疤痕医用敷料,其特征在于,所述背衬层为具有粘结作用的医用透气贴膜为医用聚氨酯薄膜、离型膜或医用背衬膜。
6.根据权利要求1~4中任一项所述的具有组织诱导功能的淡化疤痕医用敷料,其特征在于,所述医用聚氨酯膜片的材料构优选以赖氨酸二异氰酸酯做硬段的聚氨酯,软段可以是以聚乙二醇为引发剂,LA、GA、CL、PDO、己二酸酐得聚合物二醇,扩链接选自扩链剂二元醇或二元胺或类二元胺,具体选自乙二醇、二甘醇、四甘醇、1,3- 丙二醇、1,4- 丁二醇、1,6-己二醇、1,7- 庚二醇、1,8- 辛二醇、1,9- 壬二醇、1,10- 癸二醇、乙二胺、丙二胺、丁二胺、戊二胺、类二元胺中的一种或两种;
所述医用聚氨酯膜片采用如下几种制备方法:
第一种:使用不同比例的CL、PDO和不同分子量的PEG合成线型聚己内酯二醇,将其产物与赖氨酸二异氰酸酯反应,使用不同的二元醇作为扩链剂,辛酸亚锡作为催化剂,反应得到医用聚氨酯膜片;
第二种:使用分子量范围为200-2000的聚乳酸如PLA、PGA、PLGA和不同二元醇合成线型乳酸-乙醇酸共聚多元醇,将产物与不同的二异氰酸酯反应,辛酸亚锡作为催化剂,反应得到医用聚氨酯膜片;
第三种:使用不同分子量的LA、GA聚合物二醇、指 已二酸聚酯二元醇、乙二酸聚酯二元醇作为软链,将其与LDI和不同小分子二醇或二胺进行反应,辛酸亚锡作为催化剂,反应得到医用聚氨酯膜片;
第四种:使用的端羟基聚二甲基硅氧烷作为软段,将其与LDI和小分子二醇或二胺进行反应,辛酸亚锡作为催化剂,形成由软段和硬段交替排列组成的有机硅-聚氨酯嵌段共聚物。
7.根据权利要求1或2所述的具有组织诱导功能的淡化疤痕医用敷料,其特征在于,所述医用聚氨酯膜片的制备材料还包括促进伤口愈合的高分子材料、具有生物抗炎活性的小分子药物、促进伤口愈合的活性成分,其中,所述高分子材料为聚乙烯醇及其衍生物、聚乙烯吡咯烷酮及其衍生物、透明质酸钠、透明质酸锌、海藻酸盐、改性海藻酸盐及其降解成氨基己糖和 N- 乙酰氨基葡萄糖的海藻酸盐中的一种或两种组合;所述小分子药物为多肽类、氨基酸以及各种抗炎药物的一种或两种组合。
8.一种具有组织诱导功能的淡化疤痕医用敷料的制备方法,其特征在于,包括如下步骤:
(1-1)通过静电纺丝或其它手段,将聚氨酯和促进伤口愈合的高分子材料纺成具有孔径为10-300μm、厚度为0.02-0.5mm的具有组织诱导功能的医用聚氨酯膜片;
(1-2)选具有强吸水作用或抗菌作用的高分子材料制备成多孔的吸液层;
(1-3)选择合适的透气膜作为背衬层;
(1-4)将步骤(1-1)、步骤(1-2)和步骤(1-3)制备的医用聚氨酯膜片、吸液层和被衬层按顺序紧密贴合,晾干或烘干,即形成具有组织诱导功能的淡化疤痕医用敷料。
9.一种具有组织诱导功能的淡化疤痕医用敷料的制备方法,其特征在于,包括如下步骤:
(2-1)通过聚氨酯用有机溶解溶解,浇筑工艺制成具有孔径为10-300μm、厚度为0.02-0.5mm的具有组织诱导功能的医用聚氨酯膜片,均匀喷涂上硅凝胶;
(2-2)选具有强吸水作用或抗菌作用的高分子材料制备成多孔的吸液层;
(2-3)选择合适的透气膜作为背衬层;
(2-4)步骤(2-1)、步骤(2-2)和步骤(2-3)制备的医用聚氨酯膜片、吸液层和被衬层按顺序紧密贴合,晾干或烘干,即形成具有组织诱导功能的淡化疤痕医用敷料;
10.一种具有组织诱导功能的淡化疤痕医用敷料的制备方法,其特征在于,包括如下步骤:
(3-1)将聚氨酯溶于有机溶剂中,加水和乳化剂搅拌后制成粘稠乳液状,真空干燥或冻干制成具有孔径为10-300μm、厚度为0.02-0.5mm的具有组织诱导功能的多孔医用聚氨酯膜片;
(3-2)选具有强吸水作用或抗菌作用的高分子材料制备成多孔的吸液层;
(3-3)选择合适的透气膜作为背衬层;
(3-4)将步骤(3-1)、步骤(3-2)和步骤(3-3)制备的医用聚氨酯膜片、吸液层和被衬层按顺序紧密贴合,晾干或烘干,即形成具有组织诱导功能的淡化疤痕医用敷料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810143484.3A CN108392667A (zh) | 2018-02-12 | 2018-02-12 | 具有组织诱导功能的淡化疤痕医用敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810143484.3A CN108392667A (zh) | 2018-02-12 | 2018-02-12 | 具有组织诱导功能的淡化疤痕医用敷料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108392667A true CN108392667A (zh) | 2018-08-14 |
Family
ID=63096453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810143484.3A Withdrawn CN108392667A (zh) | 2018-02-12 | 2018-02-12 | 具有组织诱导功能的淡化疤痕医用敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108392667A (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108888798A (zh) * | 2018-09-12 | 2018-11-27 | 圆容生物医药无锡有限公司 | 一种柔性可折叠生物膜及其制备方法 |
CN109303703A (zh) * | 2018-10-24 | 2019-02-05 | 圆容生物医药无锡有限公司 | 一种塑形面部提升物及其用途 |
CN109394734A (zh) * | 2018-09-11 | 2019-03-01 | 杭州美善明康生物科技有限责任公司 | 除疤痕的固体皮肤胶贴的制备方法 |
CN110124112A (zh) * | 2019-04-02 | 2019-08-16 | 华南理工大学 | 一种基于埃洛石和精氨酸改性聚酯脲氨酯复合材料及其制备与应用 |
CN110644232A (zh) * | 2019-09-20 | 2020-01-03 | 南通大学 | 一种天然抗菌保水面膜的制备方法 |
CN111808308A (zh) * | 2020-07-20 | 2020-10-23 | 浙江百得利制革有限公司 | 一种可用于医用敷料的环保pu膜及其制备工艺 |
CN113026198A (zh) * | 2019-12-09 | 2021-06-25 | 中昊晨光化工研究院有限公司 | 一种功能性敷料及其制备方法 |
CN113425501A (zh) * | 2021-05-31 | 2021-09-24 | 振德医疗用品股份有限公司 | 一种负压引流护创敷料及负压引流护创装置 |
CN116983144A (zh) * | 2023-09-22 | 2023-11-03 | 江苏信立康医疗科技有限公司 | 一种基于可降解聚羟基硅酸乙酯纤维敷料及其加工方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4360015A (en) * | 1981-05-14 | 1982-11-23 | Hartford Corporation | Multilayer absorbent structure |
CN101503501A (zh) * | 2009-03-02 | 2009-08-12 | 四川大学 | 可生物降解的无毒两亲性多嵌段聚氨酯材料及其制备方法 |
CN102600019A (zh) * | 2012-03-09 | 2012-07-25 | 烟台万利医用品有限公司 | 一种医用水凝胶敷料及其制备方法 |
US20130295081A1 (en) * | 2008-10-30 | 2013-11-07 | Vanderbilt University | Polyurethane Composite for Wound Healing and Methods Thereof |
CN105169496A (zh) * | 2015-09-30 | 2015-12-23 | 苏州纳晶医药技术有限公司 | 一种可降解支架组合物 |
CN105457092A (zh) * | 2015-10-12 | 2016-04-06 | 圆容生物医药无锡有限公司 | 一种弹性模量可调聚氨酯组合物及其在医用植入材料中的应用 |
CN107638587A (zh) * | 2017-09-25 | 2018-01-30 | 凯斯蒂南京医疗器械有限公司 | 具有组织诱导功能的无疤痕再生医用敷料及其制备方法 |
-
2018
- 2018-02-12 CN CN201810143484.3A patent/CN108392667A/zh not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4360015A (en) * | 1981-05-14 | 1982-11-23 | Hartford Corporation | Multilayer absorbent structure |
US20130295081A1 (en) * | 2008-10-30 | 2013-11-07 | Vanderbilt University | Polyurethane Composite for Wound Healing and Methods Thereof |
CN101503501A (zh) * | 2009-03-02 | 2009-08-12 | 四川大学 | 可生物降解的无毒两亲性多嵌段聚氨酯材料及其制备方法 |
CN102600019A (zh) * | 2012-03-09 | 2012-07-25 | 烟台万利医用品有限公司 | 一种医用水凝胶敷料及其制备方法 |
CN105169496A (zh) * | 2015-09-30 | 2015-12-23 | 苏州纳晶医药技术有限公司 | 一种可降解支架组合物 |
CN105457092A (zh) * | 2015-10-12 | 2016-04-06 | 圆容生物医药无锡有限公司 | 一种弹性模量可调聚氨酯组合物及其在医用植入材料中的应用 |
CN107638587A (zh) * | 2017-09-25 | 2018-01-30 | 凯斯蒂南京医疗器械有限公司 | 具有组织诱导功能的无疤痕再生医用敷料及其制备方法 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109394734A (zh) * | 2018-09-11 | 2019-03-01 | 杭州美善明康生物科技有限责任公司 | 除疤痕的固体皮肤胶贴的制备方法 |
CN108888798A (zh) * | 2018-09-12 | 2018-11-27 | 圆容生物医药无锡有限公司 | 一种柔性可折叠生物膜及其制备方法 |
CN109303703A (zh) * | 2018-10-24 | 2019-02-05 | 圆容生物医药无锡有限公司 | 一种塑形面部提升物及其用途 |
CN110124112A (zh) * | 2019-04-02 | 2019-08-16 | 华南理工大学 | 一种基于埃洛石和精氨酸改性聚酯脲氨酯复合材料及其制备与应用 |
CN110644232A (zh) * | 2019-09-20 | 2020-01-03 | 南通大学 | 一种天然抗菌保水面膜的制备方法 |
CN113026198A (zh) * | 2019-12-09 | 2021-06-25 | 中昊晨光化工研究院有限公司 | 一种功能性敷料及其制备方法 |
CN113026198B (zh) * | 2019-12-09 | 2022-07-08 | 中昊晨光化工研究院有限公司 | 一种功能性敷料及其制备方法 |
CN111808308A (zh) * | 2020-07-20 | 2020-10-23 | 浙江百得利制革有限公司 | 一种可用于医用敷料的环保pu膜及其制备工艺 |
CN111808308B (zh) * | 2020-07-20 | 2022-08-23 | 浙江百得利制革有限公司 | 一种可用于医用敷料的环保pu膜及其制备工艺 |
CN113425501A (zh) * | 2021-05-31 | 2021-09-24 | 振德医疗用品股份有限公司 | 一种负压引流护创敷料及负压引流护创装置 |
CN116983144A (zh) * | 2023-09-22 | 2023-11-03 | 江苏信立康医疗科技有限公司 | 一种基于可降解聚羟基硅酸乙酯纤维敷料及其加工方法 |
CN116983144B (zh) * | 2023-09-22 | 2023-12-01 | 江苏信立康医疗科技有限公司 | 一种基于可降解聚羟基硅酸乙酯纤维敷料及其加工方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108392667A (zh) | 具有组织诱导功能的淡化疤痕医用敷料及其制备方法 | |
CN107638587A (zh) | 具有组织诱导功能的无疤痕再生医用敷料及其制备方法 | |
Wolf et al. | Naturally derived and synthetic scaffolds for skeletal muscle reconstruction | |
CN108888798A (zh) | 一种柔性可折叠生物膜及其制备方法 | |
Anitha et al. | Chitin and chitosan in selected biomedical applications | |
Sikka et al. | The role of biopolymers and biodegradable polymeric dressings in managing chronic wounds | |
CN109503797A (zh) | 一种具有抗菌活性的医用可降解聚氨酯及其用途 | |
TW201223563A (en) | Medical dressing and negative pressure wound therapy apparatus using the same | |
Golas et al. | Tissue engineering for plastic surgeons: a primer | |
Qin et al. | Recent advances in bioengineered scaffolds for cutaneous wound healing | |
Kohli et al. | Synthetic polymers for skin biomaterials | |
CN102475920A (zh) | 一种抗炎症药物及生长因子缓释体系制备方法和应用 | |
CN111359010A (zh) | 用于修复皮肤损伤的干细胞凝胶前体组合物、其组织工程组合物使用盒及应用 | |
CN108159025A (zh) | 一种聚氨酯宫颈修复膜及其制备方法 | |
Farzamfar et al. | Polycaprolactone/gelatin nanofibrous scaffolds for tissue engineering | |
CN102343110A (zh) | 消炎促愈合复合功能防粘连载药敷料 | |
CN108338844B (zh) | 一种可降解皮肤扩张器 | |
Paul et al. | A pragmatic review on the property, role and significance of polymers in treating diabetic foot ulcer | |
Miri et al. | Updates on polyurethane and its multifunctional applications in biomedical engineering | |
Pal Kaur et al. | Material couture for wound healing and regeneration: an overview | |
AU2019223434A1 (en) | Multilayer composite material | |
CN210056890U (zh) | 一种柔性可折叠生物膜 | |
Priddy-Arrington et al. | Proactive biomaterials for chronic wound management and treatment | |
TWI247614B (en) | Wound dressing | |
Eslahi et al. | How biomimetic nanofibers advance the realm of cutaneous wound management: The state-of-the-art and future prospects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180814 |